156 related articles for article (PubMed ID: 35578065)
21. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
Gao S; Li X; Zang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
[TBL] [Abstract][Full Text] [Related]
22. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
Zhang N; Sun P; Jin H; Yang Y; Zhao Q; Zhou L; Guo L; Yang X; Lu L
Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
[TBL] [Abstract][Full Text] [Related]
23. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
[TBL] [Abstract][Full Text] [Related]
24. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
Wu YF; Ou CC; Chien PJ; Chang HY; Ko JL; Wang BY
Phytomedicine; 2019 Mar; 56():94-102. PubMed ID: 30668358
[TBL] [Abstract][Full Text] [Related]
25. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
26. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
Liu L; Chen B; Qin S; Li S; He X; Qiu S; Zhao W; Zhao H
Biochem Biophys Res Commun; 2010 Feb; 392(2):190-5. PubMed ID: 20060381
[TBL] [Abstract][Full Text] [Related]
27. The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV-infected patients on suppressive antiretroviral therapy.
Li JH; Ma J; Kang W; Wang CF; Bai F; Zhao K; Yao N; Liu Q; Dang BL; Wang BW; Wei QQ; Kang WZ; Sun YT
HIV Med; 2020 Dec; 21(11):747-757. PubMed ID: 33369029
[TBL] [Abstract][Full Text] [Related]
28. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
Li Z; Zhang J; Zhou M; Li JL; Qiu QC; Fu JH; Xue SL; Qiu HY
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35103292
[TBL] [Abstract][Full Text] [Related]
30. Ganoderma immunomodulatory protein and chidamide down-regulate integrin-related signaling pathway result in migration inhibition and apoptosis induction.
Lu CT; Leong PY; Hou TY; Huang SJ; Hsiao YP; Ko JL
Phytomedicine; 2018 Dec; 51():39-47. PubMed ID: 30466626
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of Chidamide in hepatocellular carcinoma cell lines.
Wang H; Guo Y; Fu M; Liang X; Zhang X; Wang R; Lin C; Qian H
Mol Med Rep; 2012 Jun; 5(6):1503-8. PubMed ID: 22484326
[TBL] [Abstract][Full Text] [Related]
32.
Yu J; Zhang X; Ma Y; Li Z; Tao R; Chen W; Xiong S; Han X
Cancer Biother Radiopharm; 2021 Feb; 36(1):95-105. PubMed ID: 32552008
[No Abstract] [Full Text] [Related]
33. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
He J; Chen Q; Gu H; Chen J; Zhang E; Guo X; Huang X; Yan H; He D; Yang Y; Zhao Y; Wang G; He H; Yi Q; Cai Z
Haematologica; 2018 Aug; 103(8):1369-1379. PubMed ID: 29773595
[TBL] [Abstract][Full Text] [Related]
34. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
Cao HY; Li L; Xue SL; Dai HP
Hematol Oncol; 2023 Aug; 41(3):301-309. PubMed ID: 36251458
[TBL] [Abstract][Full Text] [Related]
35. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus.
Yang W; Sun Z; Hua C; Wang Q; Xu W; Deng Q; Pan Y; Lu L; Jiang S
Microbes Infect; 2018; 20(9-10):626-634. PubMed ID: 29126877
[TBL] [Abstract][Full Text] [Related]
36. Chidamide, a novel histone deacetylase inhibitor, inhibits laryngeal cancer progression in vitro and in vivo.
Liu X; Li W; Xu L; Chen X; Zhao R; Guo Y; Ge J; Yang Z; Li L; Zhang J; Cao J; Shao Y; Guo X; Tian L; Liu M
Int J Biochem Cell Biol; 2023 May; 158():106398. PubMed ID: 36933859
[TBL] [Abstract][Full Text] [Related]
37. Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
Zhang L; Kang W; Lu X; Ma S; Dong L; Zou B
Gene; 2019 Jan; 681():15-25. PubMed ID: 30266498
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
Zhao L; Lv C; Sun L; Li Q; Wang Y; Wu M; Wang Y; Guo Z; Bian S; Kong D; Lin L; Wang Y; Zhou J; Li Y
Invest New Drugs; 2021 Aug; 39(4):961-970. PubMed ID: 33566253
[TBL] [Abstract][Full Text] [Related]
39. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
Singh A; Chang TY; Kaur N; Hsu KC; Yen Y; Lin TE; Lai MJ; Lee SB; Liou JP
Eur J Med Chem; 2021 Apr; 215():113169. PubMed ID: 33588178
[TBL] [Abstract][Full Text] [Related]
40. Targeting HDACs for diffuse large B-cell lymphoma therapy.
Wu C; Song Q; Gao S; Wu S
Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
